- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema
Diabetic Retinopathy Market size was valued at USD 6.24 billion in 2022 and is poised to grow at a CAGR of 7.1% from 2023-2029. Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects the people with diabetes from number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation in diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy market is not properly treated, can progressively become more serious and seriously affects vision which may leads to blindness. Diabetic retinopathy can be treated by various methods depending on the stage of disease. Diabetic retinopathy is one of the major causes of blindness in adult population in America. As per, World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population are having diabetic retinopathy. An increase in focus on Asia-pacific and LAMEA regions by various vendors is expected to boost the diabetic retinopathy market growth of the market According to the World Bank, in 2015,10.4% of rate of prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.
Global Diabetic Retinopathy Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.1%
Largest Market
North America
Fastest Growing Market
Europe
Diabetic Retinopathy Market Dynamics
Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation (WHO), 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure up-gradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the diabetic retinopathy market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of diabetic retinopathy market.
North-America Got Significant Share of
Diabetic Retinopathy Market Regional Analysis
On the basis of regions, the global market of diabetic retinopathy has been segmented into five key regions, Latin America North America, Asia-Pacific, Europe, and Middle East & Africa. North America dominates the market followed by Asia-Pacific and Europe. The factors that are attributing for the market growth in North America are, people with high obesity rates are more prone to diabetes conditions. Large patient pool in European region with diabetic retinopathy is expected to drive the growth of the market. In emerging economies, due to the improvement in the healthcare infrastructure and rise in awareness in the people Owing to improved infrastructure and awareness among the people, improving on the quality of life (QALY) in diabetic patients, rise in demand of early detection and treatment of chronic conditions such as diabetic retinopathy are the factors that are driving the growth of the diabetic retinopathy market in Asia Pacific regions.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The diabetic retinopathy market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Diabetic Retinopathy Market Segmentation
By Type
By Drug Class
- Corticosteroids
- Anti-VEGF (vascular endothelial growth factor)
By Distribution Channel
- Ophthalmic Clinics
- Hospital Pharmacies
- Retail pharmacies
Frequently Asked Questions
The diabetic retinopathy market size was valued at USD 6.24 billion in 2022
Abbott Laboratories (U.S.), Alimera Sciences (U.S.), Allergan plc (Ireland.), Ampio Pharmaceuticals. (U.S.), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Valeant (Canada)
Europe is the fastest-growing region in the diabetic retinopathy market
| 1. Executive Summary |
| 2. Global Diabetic Retinopathy Market Introduction |
| 2.1. Global Diabetic Retinopathy Market - Taxonomy |
| 2.2. Global Diabetic Retinopathy Market - Definitions |
| 2.2.1. Drug Type |
| 2.2.2. Route of Administration |
| 2.2.3. Distribution Channel |
| 3. Global Diabetic Retinopathy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Diabetic Retinopathy Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Diabetic Retinopathy Treatment Market – Competition Landscape |
| 4. Global Diabetic Retinopathy Market, By Drug Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.1. Aflibercept |
| 4.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3. Market Opportunity Analysis |
| 4.2. Ranibizumab |
| 4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 4.3. Corticosteroids |
| 4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.3. Market Opportunity Analysis |
| 4.4. Others |
| 4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.4.3. Market Opportunity Analysis |
| 5. Global Diabetic Retinopathy Treatment Market Forecast, By Route of Administration, 2018-2022 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
| 5.1. Oral |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Parenteral |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Diabetic Retinopathy Treatment Market, By Distribution Channel, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1. HOSPITAL PHARMACIES |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. RETAIL PHARMACIES |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. ONLINE PHARMACIES |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Diabetic Retinopathy Treatment Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel and Region, 2023-2029 |
| 8. North America Diabetic Retinopathy Treatment MarketAnalysis,2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1. By Drug Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Aflibercept |
| 8.1.2. Ranibizumab |
| 8.1.3. Corticosteroids |
| 8.1.4. Others |
| 8.2. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Oral |
| 8.2.2. Parenteral |
| 8.2.3. Others |
| 8.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. HOSPITAL PHARMACIES |
| 8.3.2. RETAIL PHARMACIES |
| 8.3.3. ONLINE PHARMACIES |
| 8.4. Country Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.4.1. USA |
| 8.4.2. Canada |
| 8.5. North America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2023-2029 |
| 8.6. North America Diabetic Retinopathy Treatment Market Dynamics – Trends |
| 9. Europe Diabetic Retinopathy Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.1. By Drug Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Aflibercept |
| 9.1.2. Ranibizumab |
| 9.1.3. Corticosteroids |
| 9.1.4. Others |
| 9.2. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Oral |
| 9.2.2. Parenteral |
| 9.2.3. Others |
| 9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. HOSPITAL PHARMACIES |
| 9.3.2. RETAIL PHARMACIES |
| 9.3.3. ONLINE PHARMACIES |
| 9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. Germany |
| 9.4.2. UK |
| 9.4.3. France |
| 9.4.4. Spain |
| 9.4.5. Italy |
| 9.4.6. Russia |
| 9.4.7. Poland |
| 9.4.8. Rest of Europe |
| 9.5. Europe Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2023-2029 |
| 9.6. Europe Diabetic Retinopathy Treatment Market Dynamics – Trends |
| 10. Asia-Pacific Diabetic Retinopathy Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 10.1. By Drug Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Aflibercept |
| 10.1.2. Ranibizumab |
| 10.1.3. Corticosteroids |
| 10.1.4. Others |
| 10.2. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Oral |
| 10.2.2. Parenteral |
| 10.2.3. Others |
| 10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. HOSPITAL PHARMACIES |
| 10.3.2. RETAIL PHARMACIES |
| 10.3.3. ONLINE PHARMACIES |
| 10.4. Country Analysis2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Japan |
| 10.4.2. China |
| 10.4.3. India |
| 10.4.4. ASEAN |
| 10.4.5. Australia & New Zealand |
| 10.4.6. Rest of Asia-Pacific |
| 10.5. Asia-Pacific Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2023-2029 |
| 10.6. Asia-Pacific Diabetic Retinopathy Treatment Market Dynamics – Trends |
| 11. Latin America Diabetic Retinopathy Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 11.1. By Drug Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Aflibercept |
| 11.1.2. Ranibizumab |
| 11.1.3. Corticosteroids |
| 11.1.4. Others |
| 11.2. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Oral |
| 11.2.2. Parenteral |
| 11.2.3. Others |
| 11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. HOSPITAL PHARMACIES |
| 11.3.2. RETAIL PHARMACIES |
| 11.3.3. ONLINE PHARMACIES |
| 11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Brazil |
| 11.4.2. Mexico |
| 11.4.3. Argentina |
| 11.4.4. Rest of Latin America |
| 11.5. Latin America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2023-2029 |
| 11.6. Latin America Diabetic Retinopathy Treatment Market Dynamics – Trends |
| 12. Middle East and Africa Diabetic Retinopathy Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 12.1. By Drug Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Aflibercept |
| 12.1.2. Ranibizumab |
| 12.1.3. Corticosteroids |
| 12.1.4. Others |
| 12.2. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Oral |
| 12.2.2. Parenteral |
| 12.2.3. Others |
| 12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. HOSPITAL PHARMACIES |
| 12.3.2. RETAIL PHARMACIES |
| 12.3.3. ONLINE PHARMACIES |
| 12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Gulf Cooperation Council (GCC) Countries |
| 12.4.2. Israel |
| 12.4.3. South Africa |
| 12.4.4. Rest of MEA |
| 12.5. MEA Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2023-2029 |
| 12.6. MEA Diabetic Retinopathy Treatment Market Dynamics – Trends |
| 13. Global Diabetic Retinopathy Treatment - Pipeline Drug Analysis |
| 13.1. Global Diabetic Retinopathy Treatment Disease Epidemiology |
| 13.2 Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment |
| 13.3. Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment - Sponsors/Companies |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Regeneron Pharmaceuticals |
| 14.2.2. Novartis AG |
| 14.2.3. Genentech |
| 14.2.4. Novartis AG |
| 14.2.5. Bayer AG |
| 14.2.6. Oxurion |
| 14.2.7. OccuRx |
| 14.2.8. AptaBio Therapeutics |
| 14.2.9. Kodiak Sciences |
| 14.2.10. RemeGen |
| 14.2.11. F. Hoffman-La-Roche AG. |
| 14.2.12. Grifols S.A. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronymsc |
- Abbott Laboratories (U.S.)
- Alimera Sciences (U.S.)
- Allergan plc (Ireland.)
- Ampio Pharmaceuticals. (U.S.)
- Bayer AG (Germany)
- F. Hoffmann-La Roche (Switzerland)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Valeant (Canada)